Acrivon Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
Acrivon Therapeutics, Inc. filed a Form 8-K dated June 22, 2023, reporting the results of its 2023 annual meeting of stockholders. The company is a Nasdaq-listed emerging growth company trading under the symbol ACRV.
Annual Meeting Results
A quorum of 17,880,383 shares, representing 81.55% of the outstanding voting shares as of the April 24, 2023 record date, was present or represented by proxy. All three proposals were approved.
| Proposal | Result | Vote Details |
|---|---|---|
| Election of Michael Tomsicek, M.B.A. as a Class I director | Elected through the 2026 annual meeting | For: 17,527,002; Withheld: 226,168; Broker non-votes: 127,213 |
| Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 | Ratified | For: 17,879,658; Against: 725; Abstain: 0 |
| Election of Charles Baum, M.D., Ph.D. as a Class I director | Elected through the 2026 annual meeting | For: 17,660,794; Withheld: 91,113; Broker non-votes: 128,476 |
Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes, Outlook, and Risks
The filing reports no operational or financial guidance, outlook, contingencies, unusual items, or material business changes. Its disclosures are limited to annual meeting voting results and director elections.
Important Facts to Verify
- Confirm the elected terms and subsequent board composition for Michael Tomsicek and Charles Baum.
- Verify the appointment and audit work of PricewaterhouseCoopers LLP for the fiscal year ending December 31, 2023.
- Review the company’s quarterly and annual filings for financial performance, cash runway, funding needs, clinical development updates, and risk factors, which are not addressed in this Form 8-K.